- Vertex Energy (VTNR) +28%.
- Cloudera CLDR +24% on being acquired by Clayton, Dubilier & Rice and KKR for $5.3 billion.
- Orbsat Corp Common Stock (OSAT) +19%.
- AMC Entertainment Holdings (AMC) +16% on raising $230.0 million.
- Lineage Cell Therapeutics (LCTX) +14% on update of its OpRegen trials.
- Paratek Pharmaceuticals (PRTK) +13% as FDA approves NUZYRA.
- Alithya Group Inc. (ALYA) +11% on C$12M contract win.
- Cellect Biotechnology (APOP) +9%.
- Akebia Therapeutics (AKBA) +11% as FDA accepted for filing the New Drug Application for vadadustat.
- Immutep Limited (IMMP) +10% on collaboration with Merck KGaA.
- LightInTheBox Holding (LITB) +10% on Q1 results.
- CTI BioPharma Corp. (CTIC) +10% as FDA accepted its New Drug Application for pacritinib.
- BlackBerry Limited (BB) +9%.
- Corbus Pharmaceuticals Holdings (CRBP) +9% on licensing deals for its two new monoclonal antibodies.
- TOMI Environmental Solutions (TOMZ) +9%.
- TD Holdings (GLG) +9%.
- Syros Pharmaceuticals (SYRS) +8%.
- Canaan (CAN) +8% on Q1 results.
- Peabody Energy Corporation (BTU) +8%.
- U.S. Well Services, Inc. (USWS) +8%.
- Inpixon (INPX) +8%.
- Uxin Limited (UXIN) +7%.
- Spectrum Pharmaceuticals, Inc. (SPPI) +7% as FDA has initiated its inspection of the ROLONTIS manufacturing facility.
- LexinFintech Holdings Ltd. (LX) +7% on Q1 results.
- Purple Biotech Ltd. (PPBT) +7%.